Automating Procedures for Processing, Cryopreservation, Storage, and Manipulation of Human Peripheral Blood Mononuclear Cells

Journal of Laboratory Automation

Volumn 9, Issue 1, 2004, Pages 16-23

  Cox, Josephine H ^a   Ferrari, Guido ^b   Bailer, Robert T ^c   Koup, Richard A ^c  

^a US Military HIV Research Program   (United States)

^b DUKE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

automation; blood processing; cellular immunity; cryopreservation; human clinical trials; vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN SPECIFICITY; CELL MANIPULATION; CELL VIABILITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CRYOPRESERVATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LABORATORY AUTOMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; T LYMPHOCYTE;

EID: 0842344480     PISSN: 22110682     EISSN: 15402452     Source Type: Journal    
DOI: 10.1016/S1535-5535-03-00202-8     Document Type: Article

References (54)

1. Esser M. T. Marchese R. D. Kierstead L. S. Memory T cells and vaccines. Vaccine 2003, 21, 419–430.
2. McMichael A. Rowland-Jones S. Cellular immune responses to HIV. Nature 2001, 410, 980–986.
3. Aidoo I. Udhayakumar I. Field studies of cytotoxic T lymphocytes in malaria infections: Implications for malaria vaccine development. Parasitol Today 2000, 16, 50–56.
4. Kaufmann S. H. Protection against tuberculosis: Cytokines, T cells, and macrophages. Ann. Rheum. Dis. 2002, 61(Suppl. 2), 54–58.
5. Rosenberg S. A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411, 380–384.
6. Hickling J. K. Measuring T-lymphocyte function. Expert reviews in molecular medicine. http://www.expertreviews.org (accessed Oct 1998).
7. Clay T. Hobeika A. Mosca P. Lyerly H. Morse M. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 2001, 7(5), 1127–1135.
8. Coulie P. G. Bruggen P. T-cell responses of vaccinated cancer patients. Current Opinion in Immunology 2003, 15(2), 131–137.
9. Kaul R. Rowland-Jones S. L. Methods of detection of HIV-specific CTL and their role in protection against HIV infection, Vol. 1999: HIV Molecular immunology database. http://hiv-web.lanl.gov/immuno/ (accessed 1999).
10. Russell N. D. Hudgens M. G. Ha R. Havenar-Daughton C. McElrath M. J. Moving to HIV-1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity. J. Infect. Dis. 2003, 187, 226–242.
11. Smith J. G. Liu X. Kaufhold R. M. Clair J. Caulfield M. J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to Varicella-Zoster virus. Clin. Diagn. Lab. Immunol. 2001, 8(5), 871–879.
12. Kreher C. R. Dittrich M. T. Guerkov R. Boehm B. O. Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Methods 2003, 278, 79–93.
13. Weinberg A. Betensky R. Zhang L. Ray G. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn. Lab. Immunol. 1998, 5, 804–807.
14. Tomar R. Total laboratory automation and diagnostic immunology. Clin. Diagn. Lab. Immunol. 1999, 6, 293–294.
15. Porter G. Strategies for successful laboratory automation. American Biotechnology Laboratory, 2001, p 44.
16. Evans T. Keefer M. Weinhold K. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 1999, 180(2), 290–298.
17. Spearman P. HIV vaccine development: Lessons from the past and promise for the future. Current HIV Research 2003, 1, 101–120.
18. Belshe R. Stevens C. Gorse G. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 2001, 183, 1343–1352.
19. Slater K. Cytotoxicity tests for high-throughput drug discovery. Curr. Opin. Biotechnol. 2001, 12, 70–74.
20. Wodnicka M. Guarino R. D. Hemperly J. J. Timmins M. R. Stitt D. Pitner J. B. Novel fluorescent technology platform for high throughput cytotoxicity and proliferation assays. J. Biomol. Screen. 2000, 5(3), 141–152.
21. Cory A. H. Owen T. C. Barltrop J. A. Cory J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991, 3, 207–212.
22. Berencsi K. Gyulai Z. Gonczol E. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 2001, 183, 1171–1179.
23. McElrath M. Siliciano R. Weinhold K. HIV Type 1 vaccine-induced cytotoxic T cell responses in phase i clinical trials: Detection, characterization, and quantitation. AIDS Research and Human Retroviruses 1997, 13, 211–216.
24. Betts M. R. Brenchley J. M. Price D. A. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 2003, 281, 65–78.
25. Rubio V. Stuge T. B. Singh N. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 2003, 9, 1377–1382.
26. Asemissen A. Nagorsen D. Keilholz U. Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J. Immunol. Methods 2001, 251, 101–108.
27. Karlsson A. C. Martin J. N. Younger S. R. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J. Immunol. Methods 2003, 283, 141–153.
28. Sun Y. Iglesias E. Samri A. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J. Immunol. Methods 2003, 272, 23–34.
29. Whiteside T. L. Zhao Y. Tsukishiro T. Elder E. M. Gooding W. Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 2003, 9, 641–649.
30. McConkey S. Reece W. Moorthy V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 2003, 9, 729–735.
31. Cox J. H. Ferrari G. Kalams S. A. Lopaczynski W. Oden N. D'Souza M. P. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international HIV-1 vaccine trials (submitted).
32. Mwau M. McMichael A. Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retroviruses 2002, 18, 611–618.
33. Trigona W. L. Clair J. H. Persaud N. Intracellular staining for HIV-specific IFN-gamma production: Statistical analyses establish reproducibility and criteria for distinguishing positive responses. J. Interferon Cytokine Res. 2003, 23, 369–377.
34. Klausner R. D. Fauci A. S. Corey L. The need for a global HIV vaccine enterprise. Science 2003, 300, 2036–2039.
35. Sandstrom E. Birx D. HIV vaccine trials in Africa. Aids 2002, 16(Suppl. 4), S89–S95.
36. UNAIDS. Report on the global HIV/AIDS epidemic year 2001. 2002.
37. McMichael A. Hanke T. HIV vaccines 1983–2003. Nat. Med. 2003, 9, 874–880.
38. NIAID. $85 million awarded for research on human immunity and biodefense. http://www.niaid.nih.gov/default.htm (accessed 2003).
39. Boyum A. isolation of mononuclear cells and granulocytes from human blood. Scand J. Clin. Lab. Invest. 1968, 21, 77–89.
40. Biosciences B. http://www.bd.com/vacutainer/products/molecular/heparin/ (accessed 2003).
41. Greiner http://www.GreinerBioOneInc.com (accessed 2003).
42. Sigma. http://www.sigmaaldrich.com/ (accessed 2003).
43. Cox J. deSouza M. Ratto-Kim S. Ferrari G. Weinhold K. Birx D. Accomplishing cellular immune assays for evaluation of vaccine efficacy in developing countries. In Manual of Clinical Laboratory Immunology; 6th ed., vol. section E, chap. 33; Washington D.C: ASM Press; 2002.
44. ACTG. AIDS Clinical trial group: Consensus protocol for cryopreservation and thawing, vol. 2002: http://aactg.s-3.com/pub/download/vir/freezingprotocol.pdf (accessed 2002).
45. Nalgene Cryopreservation Manual. http://www.nalgenelabware.com/techdata/Technical/manual.asp (accessed 2003).
46. Weinberg A. Cryopreservation of peripheral blood mononuclear cells. In Manual of Clinical Laboratory Immunology; Rose N., Ed. vol. section E, chap. 23; Washington D.C: ASM Press, 2002.
47. Chapman T. Automation on the move. Nature 2003, 421, 661–666.
48. Biophile. http://www.biophileinc.com/ (accessed 2003).
49. FDA. Code of Federal Regulations Part 58. Good laboratory practise for nonclinical laboratory studies. http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfr58_01.html (accessed 2002).
50. Brush M. Laboratory information management systems help to streamline lab workflow. The Scientist 2001, 15, 23–25.
51. Ioannides C. Improving the accuracy and speed of mammalian cell counting. American Biotechnology Laboratory, 2003, p 12.
52. Guava. http://www.guavatechnologies.com/ (accessed 2003).
53. Coulter B. http://www.beckman.com/products/instrument/partChar/pc_vicell.asp (accessed 2003).
54. Lem L. Cell counting and viability assessments in the process development of cellular therapeutics. BioProcessing Journal 2003, (Jul/Aug), 57–60.